24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Weight Loss
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
22:26
Monday is doing almost everything right. Wall Street still isn’t convinced
19:44
Defense stocks soar as Israel’s new IPOs split into winners and losers
17:32
Full list of Israeli high-tech layoffs in 2026
17:30
SciPlay cuts 20 jobs at its 300-person Israeli gaming hub
More stories
Buzz
Most popular
Daily
Weekly
1
Israeli AI startup Decart nearing $6 billion sale, Musk’s SpaceX circling
2
Israel set to reject $4.2 billion Zim sale despite buyers’ concessions
3
Corma raises $60 million Seed to build AI designed to fight AI-powered cyberattacks
4
Talkspace co-founder Oren Frank dies at 60 after battle with cancer
5
Israel’s Iron Beam laser was hailed as a breakthrough. It still isn’t operational
More news
Weight Loss
4 stories about Weight Loss
Epitomee surges 200% in two days on FDA approval for weight loss pill
16.09.24
|
Adiel Eithan Mustaki
Investors are hopeful, but the company must now face an uphill battle in a crowded market.
Weight loss pill maker Epitomee’s stock sinks 70% after Nestlé cancels agreement
04.12.23
|
Adiel Eithan Mustaki
The Swiss conglomerate notified Epitomee that it has decided not to market its product as the clinical trial results measuring the disparity in the weight loss rate between patients who took the pill and the control group did not reach the previously agreed upon success level
Weight loss pill success sparks stock surge at Epitomee Medical
04.09.23
|
Adiel Eithan Mustaki
The company, which has not yet published the full results of its study, plans to seek FDA approval via the 510(k) pathway
Teva Israel to Stop Distribution of Weight Loss Drug Amid Cancer Concerns
16.02.20
|
Lilach Baumer
On Thursday, the manufacturer of Belviq weight loss drug, Eisai, announced it was withdrawing the drug from the U.S. market after a five-year trial found it increased risk of cancer by 0.6%